Chapter 11
Perspectives
11.1 Introduction
The economic growth of a nation raises the claim for a healthy eco-friendly
environment. Therefore, to avoid any disease and problems due to the adverse effect
of chiral pollutants, it is essential to monitor the chiral pollutants in our environment.
In spite of the advancement of science and technology, data on the chirality of the
different pollutants and their impact on the environment still are limited although
information on this topic is increasing (Ali and Aboul-Enein 2004; Müller and
Kohler 2004; Ye et al. 2010; Li et al. 2011; Kasprzyk-Hordern and Baker 2012;
Kunkel and Radke 2012; Ribeiro et al. 2013). In particular, drugs have emerged as a
new generation of environmental pollutants (Hühnerfuss and Shah 2009; Kunkel
and Radke 2012; Baker and Kasprzyk-Hordern 2013; Ribeiro et al. 2013, 2014;
Scheurell et al. 2013, 2014; Petrie et al. 2015; Sanganyado et al. 2016, 2017; Evans
et al. 2017; Ruan et al. 2019; Ma et al. 2020). Regulations are available for the chiral
pharmaceuticals and drugs before they get on the market (Hutt 1991; Ariens 1993;
Landoni et al. 1997; Basheer 2018; Zheng et al. 2020). United States Food and Drug
Administration (US FDA), European Committee for Proprietary Medicinal Products, Health Canada, Pharmaceutical and Medical Devices Agencies of Japan
formulated the guidelines for the production and control of racemic drugs to ensure
their safety (Aboul-Enein and Ali 2003; Nguyen et al. 2006; Basheer 2018).
Unfortunately, there is still no proper regulation available neither on national nor
on international level for controlling effectively release and presence of the chiral
pollutants in the environment (Basheer 2018; Song et al. 2020).
© Springer Nature Switzerland AG 2021
R. Kallenborn et al., Chiral Environmental Pollutants,
https://doi.org/10.1007/978-3-030-62456-9_11
307
Perspectives
11.1 Introduction
The economic growth of a nation raises the claim for a healthy eco-friendly
environment. Therefore, to avoid any disease and problems due to the adverse effect
of chiral pollutants, it is essential to monitor the chiral pollutants in our environment.
In spite of the advancement of science and technology, data on the chirality of the
different pollutants and their impact on the environment still are limited although
information on this topic is increasing (Ali and Aboul-Enein 2004; Müller and
Kohler 2004; Ye et al. 2010; Li et al. 2011; Kasprzyk-Hordern and Baker 2012;
Kunkel and Radke 2012; Ribeiro et al. 2013). In particular, drugs have emerged as a
new generation of environmental pollutants (Hühnerfuss and Shah 2009; Kunkel
and Radke 2012; Baker and Kasprzyk-Hordern 2013; Ribeiro et al. 2013, 2014;
Scheurell et al. 2013, 2014; Petrie et al. 2015; Sanganyado et al. 2016, 2017; Evans
et al. 2017; Ruan et al. 2019; Ma et al. 2020). Regulations are available for the chiral
pharmaceuticals and drugs before they get on the market (Hutt 1991; Ariens 1993;
Landoni et al. 1997; Basheer 2018; Zheng et al. 2020). United States Food and Drug
Administration (US FDA), European Committee for Proprietary Medicinal Products, Health Canada, Pharmaceutical and Medical Devices Agencies of Japan
formulated the guidelines for the production and control of racemic drugs to ensure
their safety (Aboul-Enein and Ali 2003; Nguyen et al. 2006; Basheer 2018).
Unfortunately, there is still no proper regulation available neither on national nor
on international level for controlling effectively release and presence of the chiral
pollutants in the environment (Basheer 2018; Song et al. 2020).
© Springer Nature Switzerland AG 2021
R. Kallenborn et al., Chiral Environmental Pollutants,
https://doi.org/10.1007/978-3-030-62456-9_11
307